Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

References

• Abe, K., Bridges, A. S., Yue, W., Brouwer, K. L. (2008). In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther 326:983–990
   PubMed Web of Science ®Google Scholar
• Backman, J. T., Luurila, H., Neuvonen, M., Neuvonen, P. J. (2005). Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154–167.
   PubMed Web of Science ®Google Scholar
• Fromm, M. F., Kauffmann, H. M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., et al. (2000). The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575–1580.
   PubMed Web of Science ®Google Scholar
• Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M., Tamai, I. (2008). Effect of plasma protein binding on in vitro–in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab Dispos 36:1275–1282.
   PubMed Web of Science ®Google Scholar
• Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587.
   PubMed Web of Science ®Google Scholar
• Giacomini, K. M., Sugiyama, Y. (2005). Membrane transporters and drug response. In: Brunton, L. L., Lazo, J. S., Parker, K. L., Goodman, L. S., Gilman, A. G. (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. (pp 41–70 ), McGraw-Hill Professional Publishing: New York, USA.
   Google Scholar
• Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., von Richter O., Zundler, J., et al. (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147–153.
   PubMed Web of Science ®Google Scholar
• Hirano, M., Maeda, K., Shitara, Y., Sugiyama, Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139–146.
   PubMed Web of Science ®Google Scholar
• Hirano, M., Maeda, K., Shitara, Y., Sugiyama, Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229–1236.
   PubMed Web of Science ®Google Scholar
• Hubbard, A. L., Barr, V. A., Scott, L. J. (1994). Hepatocyte surface polarity. In: Arias, I., Wolkoff, A., Boyer, J., Shafritz, D., Fausto, N., Jakoby, W. B., et al. (Eds.), The liver: biology and pathobiology. New York: Raven Press.
   Google Scholar
• Igel, M., Arnold, K. A., Niemi, M., Hofmann, U., Schwab, M., Lutjohann, D., et al. (2006). Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79:419–426.
   PubMed Web of Science ®Google Scholar
• Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., et al. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109–1115.
   PubMed Web of Science ®Google Scholar
• Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–171.
   PubMed Web of Science ®Google Scholar
• Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., et al. (2002). Regulation of multidrug resistance–associated protein 2 (ABCC2) by the nuclear receptors, pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–2915.
   PubMed Web of Science ®Google Scholar
• Kato, M., Chiba, K., Horikawa, M., Sugiyama, Y. (2005). The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236–243.
   PubMedGoogle Scholar
• Kawai, R., Lemaire, M., Steimer, J. L., Bruelisauer, A., Niederberger, W., Rowland, M. (1994). Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22:327–365.
   PubMedGoogle Scholar
• Kitamura, Y., Hirouchi, M., Kusuhara, H., Schuetz, J. D., Sugiyama, Y. (2008). Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance–associated protein 3 (Mrp3/Abcc3). J Pharmacol Exp Ther 327:465–473.
   PubMed Web of Science ®Google Scholar
• Klaassen, C. D., Slitt, A. L. (2005). Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6:309–328.
   PubMed Web of Science ®Google Scholar
• Kusuhara, H., Sugiyama, Y. (2009). In vitro–in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37–52.
   PubMed Web of Science ®Google Scholar
• Kyrklund, C., Backman, J. T., Neuvonen, M., Neuvonen, P. J. (2004). Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 57:181–187.
   PubMed Web of Science ®Google Scholar
• Lau, Y. Y., Huang, Y., Frassetto, L., Benet, L. Z. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194–204.
   PubMed Web of Science ®Google Scholar
• Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. (2008). SLCO1B1 variants and statin-induced myopathy—a genomewide study. NEJM 359:789–799.
   PubMed Web of Science ®Google Scholar
• Liu, X., LeCluyse, E. L., Brouwer, K. R., Lightfoot, R. M., Lee, J. I., Brouwer, K. L. (1999). Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289:1592–1599.
   PubMed Web of Science ®Google Scholar
• Maeda, K., Sugiyama, Y. (2008). Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic, and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23:223–235.
   PubMed Web of Science ®Google Scholar
• Matsushima, S, Maeda, K, Hayashi, H, Debori, Y, Schinkel, AH, Schuetz, JD, et al. (2008a). Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474–1483.
   PubMed Web of Science ®Google Scholar
• Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T., Sugiyama, Y. (2008b). Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663–669.
   PubMed Web of Science ®Google Scholar
• Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., et al. (2005). Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–1067.
   PubMed Web of Science ®Google Scholar
• McCuskey, R. S. (1992). Functional morphology of the liver with empahsis on microvasculature. In: Tavoloni, N., Berk, P. D. (Eds.), Hepatic transport and bile secretion: physiology and pathophysiology. New York: Raven Press.
   Google Scholar
• Milne, R. W., Larsen, L. A., Jorgensen, K. L., Bastlund, J., Stretch, G. R., Evans, A. M. (2000). Hepatic disposition of fexofenadine: influence of the transport inhibitors, erythromycin and dibromosulphothalein. Pharm Res 17:1511–1515.
   PubMed Web of Science ®Google Scholar
• Muck, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., et al. (1999). Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251–261.
   PubMed Web of Science ®Google Scholar
• Niemi, M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802.
   PubMed Web of Science ®Google Scholar
• Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M., Lutjohann, D., et al. (2005). Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genom 15:303–309.
   PubMed Web of Science ®Google Scholar
• Nies, A. T., Schwab, M., Keppler, D. (2008). Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Exp Opin Drug Metab Toxicol 4:545–568.
   PubMed Web of Science ®Google Scholar
• Niinuma, K., Kato, Y., Suzuki, H., Tyson, C. A., Weizer, V., Dabbs, J. E., et al. (1999). Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 276:G1153–G1164.
   Google Scholar
• Ohtsuka, H., Abe, T., Onogawa, T., Kondo, N., Sato, T., Oshio, H., et al. (2006). Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol 41:369–377.
   PubMed Web of Science ®Google Scholar
• Rowland, M., Toze, T. N. (1995). Clinical pharmacokinetics: concepts and application. Williams & Wilkins: Baltimore, USA.
   Google Scholar
• Sathirakul, K., Suzuki, H., Yasuda, K., Hanano, M., Sugiyama, Y. (1993a). Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion. Biol Pharm Bull 16:273–279.
   PubMed Web of Science ®Google Scholar
• Sathirakul, K., Suzuki, H., Yasuda, K., Hanano, M., Tagaya, O., Horie, T., et al. (1993b). Kinetic analysis of hepatobiliary transport of organic anions in Eisai-hyperbilirubinemic mutant rats. J Pharmacol Exp Ther 265:1301–1312.
   PubMed Web of Science ®Google Scholar
• Shitara, Y., Itoh, T., Sato, H., Li, A. P., Sugiyama, Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616.
   PubMed Web of Science ®Google Scholar
• Shitara, Y., Nagamatsu, Y., Wada, S., Sugiyama, Y., Horie, T. (2009). Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metab Dispos 37:1172–1178.
   PubMed Web of Science ®Google Scholar
• Takane, H, Miyata, M, Burioka, N, Shigemasa, C, Shimizu, E, Otsubo, K et al. (2006). Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 51:822–826.
   PubMed Web of Science ®Google Scholar
• Tian, X., Swift, B., Zamek-Gliszczynski, M. J., Belinsky, M. G., Kruh, G. D., Brouwer, K. L. (2008). Impact of basolateral multidrug resistance–associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36:911–915.
   PubMed Web of Science ®Google Scholar
• Tipping, E., Ketterer, B. (1981). The influence of soluble binding proteins on lipophile transport and metabolism in hepatocytes. Biochem J 195:441–452.
   PubMed Web of Science ®Google Scholar
• Ueda, K., Kato, Y., Komatsu, K., Sugiyama, Y. (2001). Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther 297:1036–1043.
   PubMed Web of Science ®Google Scholar
• Urquhart, B. L., Tirona, R. G., Kim, R. B. (2007). Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566–578.
   PubMed Web of Science ®Google Scholar
• Vavricka, S. R., Van Montfoort, J., Ha, H.R., Meier, P. J., Fattinger, K. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164–172.
   PubMed Web of Science ®Google Scholar
• Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., Sugiyama, Y. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652–662.
   PubMed Web of Science ®Google Scholar
• Yamazaki, M., Kobayashi, K., Sugiyama, Y. (1996). Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai-hyperbilirubinemic rats. Biopharm Drug Dispos 17:607–621.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski, M. J., Nezasa, K., Tian, X., Bridges, A. S., Lee, K., Belinsky, M. G., et al. (2006). Evaluation of the role of multidrug resistance–associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3−/– and Abcc4−/– mice. J Pharmacol Exp Ther 319:1485–1491.
   PubMed Web of Science ®Google Scholar
• Zelcer, N., van de Wetering, K., Hillebrand, M., Sarton, E., Kuil, A., et al. (2005). Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A 102:7274–7279.
   PubMed Web of Science ®Google Scholar